Theravance Biopharma (NASDAQ:TBPH) Announces Quarterly Earnings Results, Meets Expectations

Theravance Biopharma (NASDAQ:TBPH) posted its earnings results on Monday. The biopharmaceutical company reported $0.07 earnings per share for the quarter, meeting the consensus estimate of $0.07, Zacks reports. Theravance Biopharma had a return on equity of 18.84% and a net margin of 104.34%.

Theravance Biopharma Price Performance

TBPH opened at $16.93 on Monday. The stock has a market capitalization of $872.48 million, a PE ratio of 7.70 and a beta of 0.19. Theravance Biopharma has a 12-month low of $11.20 and a 12-month high of $21.03. The firm’s fifty day moving average price is $16.77 and its 200 day moving average price is $16.91.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. HC Wainwright downgraded shares of Theravance Biopharma from a “buy” rating to a “neutral” rating and raised their price objective for the stock from $15.00 to $17.00 in a research report on Tuesday, July 7th. JonesTrading downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Monday, June 29th. Wall Street Zen lowered Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings raised Theravance Biopharma from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 3rd. Finally, Zacks Research cut Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Monday, June 8th. Eight equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $19.40.

Insider Activity

In other Theravance Biopharma news, SVP Rhonda Farnum sold 13,314 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $16.39, for a total transaction of $218,216.46. Following the sale, the senior vice president owned 232,457 shares in the company, valued at $3,809,970.23. This represents a 5.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Eli Samaha sold 273,871 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $17.23, for a total value of $4,718,797.33. Following the completion of the sale, the insider owned 9,237,279 shares of the company’s stock, valued at $159,158,317.17. This trade represents a 2.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 350,011 shares of company stock worth $6,008,309 in the last ninety days. Corporate insiders own 7.65% of the company’s stock.

Institutional Investors Weigh In On Theravance Biopharma

Several large investors have recently added to or reduced their stakes in TBPH. Quarry LP bought a new position in shares of Theravance Biopharma during the third quarter worth about $26,000. Caitong International Asset Management Co. Ltd grew its position in Theravance Biopharma by 107.4% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 1,411 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Theravance Biopharma by 18.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 781 shares during the last quarter. CIBC Private Wealth Group LLC boosted its position in shares of Theravance Biopharma by 20,269.6% during the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock worth $68,000 after buying an additional 4,662 shares during the period. Finally, AQR Capital Management LLC bought a new position in Theravance Biopharma in the 1st quarter worth approximately $101,000. 99.10% of the stock is owned by institutional investors and hedge funds.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.